Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives

Authors: Wei Zhang, Ling Ke, Li Changqing, Yan Zhang, Wuping Li

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

To ensure the safety of plasma derivatives, screening for human parvovirus B19V genomic DNA in donated plasma using a pooling strategy is performed in some countries. We investigated the prevalence of B19V DNA and anti-B19V antibodies in Chinese plasma pools, plasma derivatives and plasma donations to evaluate the risk posed by B19V.

Methods

Using a Q-PCR assay developed in-house, we tested for B19V genomic DNA in 142 plasma pools collected between January 2009 and June 2011 from two Chinese blood products manufacturers. Plasma derivatives collected between 1993–1995 (10 batches of albumin, 155 batches of intravenous immunoglobulin, IVIG) and 2009–2011 (50 batches of albumin, 54 batches of IVIG, 35 batches of factor VIII, 7 batches of fibrinogen, and 17 batches of prothrombin complex concentrate, PCC) were also tested for B19V contamination. In addition, B19V genome prevalence in minipools(including 90 individual donations) of 49680 individual plasma samples collected between August 2011 and March 2012 by a single Chinese manufacturer was investigated. IgM/IgG was also investigated in plasma pools/derivatives and in minipools with B19V-DNA titers above 1x104 and 1x106 geq/mL using B19 ELISA IgM/IgG assay(Virion-Serion, Würzburg, Germany), respectively.

Results

B19V-DNA was detected in 54.2% of plasma pools from two Chinese blood product manufacturers; among recently produced blood products, B19V was detected in 21/54 IVIG samples, 19/35 factor VIII samples, 6/7 fibrinogen samples, and 12/17 PCC samples, but not in albumin samples. The levels of B19V-DNA in these samples varied from 102-107 geq/mL. In samples with >104 geq/mL genome DNA, B19V-specific IgG was also found in all corresponding plasma pools and IVIG, whereas none was detected in the majority of other plasma derivatives. Screening of plasma donations indicated that most minipools were contaminated with B19V-DNA (102-108 geq/mL) and one donation had 1.09 × 1010 geq/mL B19V genomic DNA along with a non-classical IgG/IgM profile.

Conclusions

Despite the implementation of some inactivation/removal methods designed to prevent viral contamination, B19V DNA was detectable in Chinese plasma pools and plasma derivatives. Thus, the introduction of B19V screening and discard donation with high viramic concentration for Chinese plasma donors would be desirable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Clewley JP: Biochemical characterization of a human parvovirus. J Gen Virol. 1984, 65 (Pt 1): 241-245.CrossRefPubMed Clewley JP: Biochemical characterization of a human parvovirus. J Gen Virol. 1984, 65 (Pt 1): 241-245.CrossRefPubMed
2.
go back to reference Cotmore SF, Tattersall P: Characterization and molecular cloning of a human parvovirus genome. Science. 1984, 226 (4679): 1161-1165. 10.1126/science.6095448.CrossRefPubMed Cotmore SF, Tattersall P: Characterization and molecular cloning of a human parvovirus genome. Science. 1984, 226 (4679): 1161-1165. 10.1126/science.6095448.CrossRefPubMed
3.
go back to reference Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP, Pereira MS: Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet. 1983, 1: 1378-CrossRefPubMed Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP, Pereira MS: Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet. 1983, 1: 1378-CrossRefPubMed
4.
go back to reference White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA: Human parvovirus arthropathy. Lancet. 1985, 1 (8426): 419-421.CrossRefPubMed White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA: Human parvovirus arthropathy. Lancet. 1985, 1 (8426): 419-421.CrossRefPubMed
5.
go back to reference Parsyan A, Candotti D: Human erythrovirus B19 and blood transfusion - an update. Transfus Med. 2007, 17: 263-278. 10.1111/j.1365-3148.2007.00765.x.CrossRefPubMed Parsyan A, Candotti D: Human erythrovirus B19 and blood transfusion - an update. Transfus Med. 2007, 17: 263-278. 10.1111/j.1365-3148.2007.00765.x.CrossRefPubMed
6.
go back to reference Cohen BJ, Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988, 25: 151-153. 10.1099/00222615-25-2-151.CrossRefPubMed Cohen BJ, Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988, 25: 151-153. 10.1099/00222615-25-2-151.CrossRefPubMed
7.
go back to reference Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE: The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zbl Bakt. 1996, 284: 232-240.CrossRef Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE: The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zbl Bakt. 1996, 284: 232-240.CrossRef
8.
go back to reference Azzi A, Morfini M, Mannucci PM: The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999, 13: 194-204. 10.1016/S0887-7963(99)80033-9.CrossRefPubMed Azzi A, Morfini M, Mannucci PM: The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999, 13: 194-204. 10.1016/S0887-7963(99)80033-9.CrossRefPubMed
9.
go back to reference Aubin JT, Defer C, Vidaud M, Maniez Montreuil M, Flan B: Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 2000, 78 (1): 7-12. 10.1046/j.1423-0410.2000.7810007.x.CrossRefPubMed Aubin JT, Defer C, Vidaud M, Maniez Montreuil M, Flan B: Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 2000, 78 (1): 7-12. 10.1046/j.1423-0410.2000.7810007.x.CrossRefPubMed
10.
go back to reference Saldanha J: Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol. 2001, 20: 7-13. 10.1016/S1386-6532(00)00149-9.CrossRefPubMed Saldanha J: Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol. 2001, 20: 7-13. 10.1016/S1386-6532(00)00149-9.CrossRefPubMed
11.
go back to reference Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J: Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang. 2001, 81: 228-235. 10.1046/j.1423-0410.2001.00120.x.CrossRefPubMed Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J: Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang. 2001, 81: 228-235. 10.1046/j.1423-0410.2001.00120.x.CrossRefPubMed
12.
go back to reference Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM: Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol. 1992, 39 (3): 228-230. 10.1002/ajh.2830390315.CrossRefPubMed Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM: Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol. 1992, 39 (3): 228-230. 10.1002/ajh.2830390315.CrossRefPubMed
13.
go back to reference Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M: Eliminating parvovirus B19 from blood products. Lancet. 1994, 343 (8900): 798-CrossRefPubMed Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M: Eliminating parvovirus B19 from blood products. Lancet. 1994, 343 (8900): 798-CrossRefPubMed
14.
go back to reference Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, Tchernia G: Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hematol. 1994, 36 (6): 449-453.PubMed Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, Tchernia G: Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hematol. 1994, 36 (6): 449-453.PubMed
15.
go back to reference Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glomstein A: Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis. 1991, 23: 675-679. 10.3109/00365549109024292.CrossRefPubMed Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glomstein A: Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis. 1991, 23: 675-679. 10.3109/00365549109024292.CrossRefPubMed
16.
go back to reference Hourfar MK, Mayr-Wohlfart U, Themann A, Sireis W, Seifried E, Schrezenmeier H, Schmidt M: Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion. 2011 Jan, 51 (1): 129-136. 10.1111/j.1537-2995.2010.02780.x.CrossRefPubMed Hourfar MK, Mayr-Wohlfart U, Themann A, Sireis W, Seifried E, Schrezenmeier H, Schmidt M: Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion. 2011 Jan, 51 (1): 129-136. 10.1111/j.1537-2995.2010.02780.x.CrossRefPubMed
17.
go back to reference Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K: Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion. 2011 Sep, 51 (9): 1887-1895. 10.1111/j.1537-2995.2010.03047.x.CrossRefPubMed Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K: Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion. 2011 Sep, 51 (9): 1887-1895. 10.1111/j.1537-2995.2010.03047.x.CrossRefPubMed
18.
go back to reference Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MY, Busch MP: A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. 2009, 114: 3677-3683. 10.1182/blood-2009-06-225706.CrossRefPubMedPubMedCentral Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MY, Busch MP: A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. 2009, 114: 3677-3683. 10.1182/blood-2009-06-225706.CrossRefPubMedPubMedCentral
19.
go back to reference Brown KE, Young NS, Alving BM, Barbosa LH: Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 2001, 41: 130-135. 10.1046/j.1537-2995.2001.41010130.x.CrossRefPubMed Brown KE, Young NS, Alving BM, Barbosa LH: Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 2001, 41: 130-135. 10.1046/j.1537-2995.2001.41010130.x.CrossRefPubMed
20.
go back to reference Tabor E, Yu MY, Hewlett I, Epstein JS: Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion. 2000, 40: 1273-1275. 10.1046/j.1537-2995.2000.40101273.x.CrossRefPubMed Tabor E, Yu MY, Hewlett I, Epstein JS: Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion. 2000, 40: 1273-1275. 10.1046/j.1537-2995.2000.40101273.x.CrossRefPubMed
21.
go back to reference Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY: Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion. 2007, 47: 883-889. 10.1111/j.1537-2995.2007.01205.x.CrossRefPubMed Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY: Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion. 2007, 47: 883-889. 10.1111/j.1537-2995.2007.01205.x.CrossRefPubMed
22.
go back to reference Siegl G, Cassinotti P: Presence and significance of parvovirus B19 in blood and blood products. Biologicals. 1998, 26: 89-94. 10.1006/biol.1998.0138.CrossRefPubMed Siegl G, Cassinotti P: Presence and significance of parvovirus B19 in blood and blood products. Biologicals. 1998, 26: 89-94. 10.1006/biol.1998.0138.CrossRefPubMed
23.
go back to reference Weimer T, Streichert S, Watson C, Gröner A: High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion. 2001, 41 (12): 1500-1504. 10.1046/j.1537-2995.2001.41121500.x.CrossRefPubMed Weimer T, Streichert S, Watson C, Gröner A: High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion. 2001, 41 (12): 1500-1504. 10.1046/j.1537-2995.2001.41121500.x.CrossRefPubMed
24.
go back to reference Prowse C, Ludlam CA, Yap PL: Human parvovirus B19 and blood products. Vox Sang. 1997, 72 (1): 1-10. 10.1046/j.1423-0410.1997.00001.x.CrossRefPubMed Prowse C, Ludlam CA, Yap PL: Human parvovirus B19 and blood products. Vox Sang. 1997, 72 (1): 1-10. 10.1046/j.1423-0410.1997.00001.x.CrossRefPubMed
25.
go back to reference He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, Yang X, Li W: Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus. 2012 Jun, 27: 1-13. He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, Yang X, Li W: Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus. 2012 Jun, 27: 1-13.
26.
go back to reference Ke L, He M, Li C, Liu Y, Gao L, Yao F, Li J, Bi X, Lv Y, Wang J: The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion. 2011 Sep, 51 (9): 1909-1918. 10.1111/j.1537-2995.2011.03067.x.CrossRefPubMed Ke L, He M, Li C, Liu Y, Gao L, Yao F, Li J, Bi X, Lv Y, Wang J: The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion. 2011 Sep, 51 (9): 1909-1918. 10.1111/j.1537-2995.2011.03067.x.CrossRefPubMed
27.
go back to reference The guideline of the technological methods and validation of viral removal/inactivation of blood products. 2002, Ministry of Health of the People's Republic of China, No. 2002–160 The guideline of the technological methods and validation of viral removal/inactivation of blood products. 2002, Ministry of Health of the People's Republic of China, No. 2002–160
28.
go back to reference Saldanha J, Minor P: Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol. 1996, 93: 714-719. 10.1046/j.1365-2141.1996.d01-1679.x.CrossRefPubMed Saldanha J, Minor P: Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol. 1996, 93: 714-719. 10.1046/j.1365-2141.1996.d01-1679.x.CrossRefPubMed
29.
go back to reference Eis-Hubinger AM, Sasowski U, Brackmann HH: Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost. 1999, 81: 476-477.PubMed Eis-Hubinger AM, Sasowski U, Brackmann HH: Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost. 1999, 81: 476-477.PubMed
30.
go back to reference Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR: Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol. 1992, 81: 407-412. 10.1111/j.1365-2141.1992.tb08248.x.CrossRefPubMed Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR: Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol. 1992, 81: 407-412. 10.1111/j.1365-2141.1992.tb08248.x.CrossRefPubMed
31.
go back to reference McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol. 1993, 31: 323-328.PubMedPubMedCentral McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol. 1993, 31: 323-328.PubMedPubMedCentral
32.
go back to reference Lefrere JJ, Mariotti M, Thauvin M: B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet. 1994, 343: 211-212. 10.1016/S0140-6736(94)90993-8.CrossRefPubMed Lefrere JJ, Mariotti M, Thauvin M: B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet. 1994, 343: 211-212. 10.1016/S0140-6736(94)90993-8.CrossRefPubMed
34.
go back to reference Bizjak G, Blondin D, Hammer R, Kozlowski P, Siegmann HJ, Stressig R: Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol. 2009, 34: 234-235.CrossRefPubMed Bizjak G, Blondin D, Hammer R, Kozlowski P, Siegmann HJ, Stressig R: Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol. 2009, 34: 234-235.CrossRefPubMed
35.
go back to reference Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F: Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol. 2009, 28: 305-309. 10.1007/s10067-008-1044-4.CrossRefPubMed Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F: Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol. 2009, 28: 305-309. 10.1007/s10067-008-1044-4.CrossRefPubMed
36.
go back to reference van Elsacker-Niele AM, Kroes AC: Human parvovirus B19: relevance in internal medicine. Neth J Med. 1999, 54: 221-230. 10.1016/S0300-2977(99)00011-X.CrossRefPubMed van Elsacker-Niele AM, Kroes AC: Human parvovirus B19: relevance in internal medicine. Neth J Med. 1999, 54: 221-230. 10.1016/S0300-2977(99)00011-X.CrossRefPubMed
37.
go back to reference Willkommen H, Schmidt I, Lower J: Safety issues for plasma derivatives and benefit from NAT testing. Biologicals. 1999, 27: 325-331. 10.1006/biol.1999.0227.CrossRefPubMed Willkommen H, Schmidt I, Lower J: Safety issues for plasma derivatives and benefit from NAT testing. Biologicals. 1999, 27: 325-331. 10.1006/biol.1999.0227.CrossRefPubMed
38.
go back to reference Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol. 1992, 39: 149-150. 10.1002/ajh.2830390217.CrossRefPubMed Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol. 1992, 39: 149-150. 10.1002/ajh.2830390217.CrossRefPubMed
39.
go back to reference Yee TT, Cohen BJ, Pasi KJ, Lee CA: Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996, 93: 457-459. 10.1046/j.1365-2141.1996.5161062.x.CrossRefPubMed Yee TT, Cohen BJ, Pasi KJ, Lee CA: Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996, 93: 457-459. 10.1046/j.1365-2141.1996.5161062.x.CrossRefPubMed
40.
go back to reference Yee TT, Lee CA, Pasi KJ: Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet. 1995, 345: 794-795.CrossRefPubMed Yee TT, Lee CA, Pasi KJ: Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet. 1995, 345: 794-795.CrossRefPubMed
Metadata
Title
Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives
Authors
Wei Zhang
Ling Ke
Li Changqing
Yan Zhang
Wuping Li
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-194

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.